IKAROS Antibody / IKZF1 (F54538)

IKZF1 Antibody Lenalidomide Degradation WB. Western blot analysis of multiple myeloma cell lysates treated with DMSO vehicle control or lenalidomide using IKZF1 Antibody demonstrates detection of IKZF1 (Ikaros) at approximately 58–75 kDa. Strong IKZF1 expression is observed in DMSO-treated cells, while treatment with lenalidomide results in a marked reduction of IKZF1 protein levels, consistent with the known cereblon-dependent degradation of Ikaros induced by immunomodulatory drugs. The reduction in signal following lenalidomide treatment supports the specificity of the antibody for IKZF1 and demonstrates its utility for monitoring pharmacologic modulation of Ikaros expression. Actin serves as a loading control. Predicted molecular weight: ~58 kDa. Observed molecular weight: approximately 58–75 kDa, consistent with known IKZF1 isoforms and post-translationally modified forms.

Western blot testing of human CEM cell lysate with IKAROS antibody. Predicted molecular weight ~58 kDa.

IKAROS Antibody Human Tonsil IHC. Immunohistochemical staining of FFPE human tonsil tissue using IKAROS Antibody demonstrates prominent nuclear HRP-DAB brown staining within subsets of lymphoid cells. The staining pattern is consistent with expression of Ikaros (IKZF1), a zinc finger transcription factor that functions as a master regulator of lymphocyte differentiation, hematopoietic development, and immune cell lineage commitment. Predominantly nuclear immunoreactivity is expected for this DNA-binding protein and highlights its critical role in controlling transcriptional programs required for normal immune system development and lymphoid cell function. The observed staining supports the utility of this antibody for immunohistochemical detection of endogenous IKZF1 in lymphoid tissues. HIER: steam section in pH6 citrate buffer for 20 min and allow to cool prior to staining.

IKAROS Antibody CEM Flow Cytometry. Flow cytometric analysis of human CEM cells stained with IKAROS Antibody demonstrates a pronounced rightward shift of the positive population (green histogram) relative to the isotype control (blue histogram). The observed fluorescence profile is consistent with expression of Ikaros (IKZF1), a zinc finger transcription factor that functions as a master regulator of lymphocyte differentiation, hematopoietic development, and immune cell lineage commitment. The clear separation between the antibody-stained and control populations supports specific detection of endogenous IKZF1 by intracellular flow cytometry and demonstrates the utility of this antibody for FACS applications. Blue = isotype control. Green = IKAROS antibody.